中国血液净化

中国血液净化 ›› 2023, Vol. 22 ›› Issue (06): 438-441.doi: 10.3969/j.issn.1671-4091.2023.06.008

• 综述 • 上一篇    下一篇

肾性贫血铁剂治疗的研究进展

唐文娇   廖若西   

  1. 610041 成都，四川大学华西医院1血液内科 2肾脏内科
  • 收稿日期:2023-02-27 修回日期:2023-03-20 出版日期:2023-06-12 发布日期:2023-06-12
  • 通讯作者: 廖若西 E-mail:lrx-scu@scu.edu.cn
  • 基金资助:
    四川省自然科学基金(2022NSFC1353)

Iron therapy for iron deficiency anemia in chronic kidney disease

TANG Wen-jiao,  LIAO Ruo-xi   

  1. Department of Hematology and 2Department of Nephrology, West China Hospital Sichuan University, Chengdu 610041, China
  • Received:2023-02-27 Revised:2023-03-20 Online:2023-06-12 Published:2023-06-12
  • Contact: 610041 成都，四川大学华西医院 E-mail:lrx-scu@scu.edu.cn

PDF

197

摘要： 肾性贫血是慢性肾脏病(chronic kidney disease,CKD)常见的并发症。CKD患者一方面常合并铁缺乏，另一方面又由于长期补铁存在铁过载风险。临床上常用的评估铁代谢的指标是铁蛋白和转铁蛋白饱和度，CKD患者由于慢性炎症状态，上述指标无法准确反映铁状态。静脉补铁和口服补铁各有优劣，多种新型铁剂的出现为未来肾性贫血铁剂治疗带来了新的选择，但其疗效仍需进一步临床验证。

关键词: 肾性贫血, 铁剂, 铁缺乏, 铁过载

Abstract: Renal anemia is a common complication of chronic kidney disease (CKD). Iron deficiency is highly prevalent in patients with CKD. On the other hand, CKD patients are vulnerable to iron overload due to long-term iron supplement. Serum transferrin and transferrin saturation are traditionally used in the evaluation of iron status. However, due to the chronic inflammation in CKD patients, these biomarkers can not reflect iron status accurately. Oral and intravenous iron therapy both show advantages and disadvantages in anemia treatment. New iron agents bring new choices for iron therapy in renal anemia, while their efficacy needs further studies.

Key words: Renal anemia, Iron therapy, Iron deficiency, Iron overload

中图分类号: